trimethyl phosphonoacetate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: trimethyl phosphonoacetate
• 英文别名: methyl dimethyl-phosphonoacetate；(1-Methoxy-2-methyl-1-oxopropan-2-yl)phosphonic acid
• 化学式: C₅H₁₁O₅P
• 分子量: 182.113
• InChiKey: SKZMFFNWDLGYSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  trimethyl phosphonoacetate 、 (4-氧代-环己基)-乙腈 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 24.17h， 生成 methyl 2-(4-(cyanomethyl)cyclohexylidene)acetate
  参考文献：
  名称：

  Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease

  摘要：

  色氮氨酸衍生的选择性纳摩尔丁酰胆碱酯酶抑制剂揭示了对抗阿尔茨海默病症状治疗具有巨大潜力。

  DOI：

  10.1039/c9cc01330j
• 作为试剂：
  描述：

  sodium methylate 、 10-methoxy-6-methyl-undec-5-en-2-one 在 trimethyl phosphonoacetate 作用下， 以 甲醇 为溶剂， 生成 Methyl-11-methoxy-3.7-dimethyldodeca-2.6-dienoat
  参考文献：
  名称：

  Biernacki,W.; Sobotka,W., Polish Journal of Chemistry, 1978, vol. 52, p. 965 - 968

  摘要：

  DOI：

文献信息

• PHOSPHODIESTERASE IV INHIBITOR CONTAINING PYRIDYLACRYLAMIDE DERIVATIVE
  申请人：TSUMURA & CO.

  公开号：EP1495757A1

  公开（公告）日：2005-01-12

  This invention relates to a phosphodiesterase IV inhibitor containing as an active ingredient a pyridylacrylamide derivative represented by the following formula (I): (wherein Ar1 represents substituted or unsubstituted pyridyl; Ar2 represents phenyl substituted by alkoxy, etc.; R1 represents hydrogen, alkyl, or aryl; R2 represents hydrogen, alkyl, cyano, or alkoxycarbonyl; R3 represents hydrogen or optionally substituted alkyl; X represents oxygen or sulfur; A and B are the same or different and each independently represents hydrogen, hydroxyl, alkoxy, or alkylthio, or A and B together represent oxo, thioxo, etc., or A may be hydroxyl and B may be 1-alkylimidazol-2-yl; and n is an integer from 1 to 3) or a pharmaceutically acceptable salt thereof.

  这项发明涉及一种磷酸二酯酶IV抑制剂，其活性成分为以下式(I)所代表的吡啶丙烯酰胺衍生物：（其中Ar1代表取代或未取代的吡啶；Ar2代表被烷氧基等取代的苯基；R1代表氢、烷基或芳基；R2代表氢、烷基、氰基或烷氧羰基；R3代表氢或可选择取代的烷基；X代表氧或硫；A和B相同或不同，每个独立代表氢、羟基、烷氧基或烷基硫基，或A和B一起代表氧代、硫代等，或A可能是羟基，B可能是1-烷基咪唑-2-基；n为1至3的整数）或其药学上可接受的盐。
• Sulfonyl derivatives
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US06525042B1

  公开（公告）日：2003-02-25

  Sulfonyl derivatives represented by general formula (I), salts of the same, and solvates of both: and application of them as drugs: [wherein R1 is hydrogen, hydroxyl, nitro or the like; R2 and R3 are each independently hydrogen, halogeno or the like; R4 and R5 are each dependently hydrogen, halogeno or the like; Q1 is an optionally substituted saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group or the like; Q2 is a single bond, oxygen or the like; Q3 is, e.g., a group represented by formula (a): T1 is carbonyl or the like; and X1 and X2 are each independently methylidyne or nitrogen]. These compounds exhibit potent Fxa inhibiting activities and serve as excellent anticoagulants which speedily exert satisfactory and persistent anti-thrombotic effects through oral administration and little cause adverse effects.

  通用公式(I)表示的磺酰衍生物，其盐以及两者的溶剂化合物：以及它们作为药物的应用：[其中R1是氢、羟基、硝基或类似物；R2和R3各自独立地是氢、卤素或类似物；R4和R5各自依赖于氢、卤素或类似物；Q1是可选择取代的饱和或不饱和的5-或6-成员环烃基或类似物；Q2是单键、氧或类似物；Q3是，例如，由公式(a)表示的基团：T1是羰基或类似物；X1和X2各自独立地是甲基亚砜或氮。这些化合物表现出强大的Fxa抑制活性，并作为优秀的抗凝血剂，通过口服迅速产生令人满意且持久的抗血栓效果，并几乎不引起不良反应。
• CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170253554A1

  公开（公告）日：2017-09-07

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein coupled receptor modulators which may be used as medicaments

  本发明提供了Formula（I）的化合物：或其立体异构体，或其药用可接受盐，其中所有变量如本文所定义。这些化合物是GPR120 G蛋白偶联受体调节剂，可以用作药物。
• Total stereocontrolled synthesis of a novel pyrrolizidine iminosugar
  作者：Martina De Angelis、Ludovica Primitivo、Federica Lizzio、Sonia Agostinelli、Carla Sappino、Ilaria Ben Romdan、Luciano Bonanni、Andrea D'Annibale、Roberto Antonioletti、Alessandra Ricelli、Giuliana Righi

  DOI：10.1016/j.carres.2021.108484

  日期：2022.1

  Herein we describe a versatile approach to the pyrrolizidine alkaloids skeleton by tailoring our original strategy already used for the pyrrolidine iminosugars synthesis. The key steps are the regio- and stereoselective azidolysis of the suitable chiral vinyl epoxide and then asymmetric dihydroxylation of the corresponding azido alcohol by using (DHQ)2AQN as the ligand. Further optimized elaborations

  在此，我们通过定制我们已经用于吡咯烷亚氨基糖合成的原始策略来描述吡咯烷生物碱骨架的通用方法。关键步骤是合适的手性乙烯基环氧化物的区域选择性和立体选择性叠氮解，然后使用 (DHQ) 2 AQN 作为配体对相应的叠氮醇进行不对称二羟基化。针对两个环闭合的进一步优化设计使我们能够通过完全立体控制实现目标亚氨基糖。吡咯里西啶亚氨基糖的广泛生物学特性使其成为新药研究的重点，因此开发获得它们的合成策略具有决定性意义。
• Synthesis and evaluation of 4-cycloheptylphenols as selective Estrogen receptor-β agonists (SERBAs)
  作者：K.L.Iresha Sampathi Perera、Alicia M. Hanson、Sergey Lindeman、Andrea Imhoff、Xingyun Lu、Daniel S. Sem、William A. Donaldson

  DOI：10.1016/j.ejmech.2018.08.006

  日期：2018.9

  A short and efficient route to 4-(4-hydroxyphenyl)cycloheptanemethanol was developed, which resulted in the preparation of a mixture of 4 stereoisomers. The stereoisomers were separated by preparative HPLC, and two of the stereoisomers identified by X-ray crystallography. The stereoisomers, as well as a small family of 4-cycloheptylphenol derivatives, were evaluated as estrogen receptor-beta agonists

  开发了一种短而有效的制备4-（4-羟苯基）环庚烷甲醇的途径，从而制备了四种立体异构体的混合物。通过制备型HPLC分离立体异构体，并通过X射线晶体学鉴定两种立体异构体。立体异构体以及一小部分4-环庚基苯酚衍生物被评估为雌激素受体-β激动剂。相对于其他七个核激素受体而言，铅化合物4-（4-羟苯基）环庚烷甲醇具有选择性激活ER的能力，对β的选择性是α亚型的300倍，EC 50在基于细胞的细胞中的EC 50为30-50 nM。直接结合测定。